Identification of a lead hypoxia-activated irreversible pan-HER inhibitor SN32807 (PR509) by pharmacokinetic and anti-tumor efficacy screening in an erlotinib-resistant xenograft model
JavaScript is disabled for your browser. Some features of this site may not work without it.
Identification of a lead hypoxia-activated irreversible pan-HER inhibitor SN32807 (PR509) by pharmacokinetic and anti-tumor efficacy screening in an erlotinib-resistant xenograft model